Klaus W. Freivogel

Loerrach, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.

Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.

Journal: Pharmaceutical medicine

Published: January 15, 2020

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Journal: Melanoma research

Published: May 17, 2019

A prospective observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study).

A prospective observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study).

Journal: The British journal of dermatology

Published: November 30, 2018

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).

Journal: Cancer

Published: September 27, 2017

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study.

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: July 21, 2017

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Published: June 15, 2015

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).

Journal: Lupus

Published: September 24, 2013

Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.

Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: May 15, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026